Incretin‐based drugs and Retinopathy risk in Medicare Enrollees

Study type

• Study type:
  Non-interventional study
• Scope of the study:
  Assessment of risk minimisation measure implementation or effectiveness

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (A10) DRUGS USED IN DIABETES

  DRUGS USED IN DIABETES
• Medical condition to be studied:
  Retinopathy

  Diabetes mellitus

Population studied

• Age groups:
  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Estimated number of subjects:
  350000

Study design details

• Main study objective:
  To examine the effect of initiation of incretin‐based therapies (IBRx) relative to other antidiabetic therapies (CompRx) on the incidence of retinopathy based on an active comparator new‐user study design.
• Outcomes:
  Incident Retinopathy
• Data analysis plan:
  IBRx new-users will be compared with new users of CompRx with respect to incidence of retinopathy diagnosis. We will use propensity scores to balance measured risk factors for retinopathy between these cohorts. Hazard rates for retinopathy will be estimated using a Cox proportional hazards model controlling for age and sex as well as any covariates remaining imbalanced after implementation of the propensity score.